For the second year running, Monash University has been ranked number two in the world for Pharmacy and Pharmacology in the 2024 Quacquarelli Symonds (QS) World University Rankings by Subject.
The University has retained its long-held position as Australia and the Asia-Pacific’s number one University for Pharmacy and Pharmacology, and has consistently ranked in the most elite group of Pharmacy and Pharmacology programs worldwide, with an average top three ranking for the last eight years.
Professor Arthur Christopoulos FAA FAHMS, Dean of Monash’s Faculty of Pharmacy and Pharmaceutical Sciences, said the University’s routinely high ranking in this subject area is attributed to the talent and continuous drive of those behind the research, practice and education.
“Over the past year the Faculty of Pharmacy and Pharmaceutical Sciences has continued to grow and evolve our education and research programs, establish multiple new spin-outs and initiatives, form new partnerships and lead the way with programs to foster equity, diversity and inclusion,” said Professor Christopoulos.
“Together, our staff and our colleagues across the entire spectrum of Monash University’s biomedical ecosystem have created an education and research environment enabling everyone to thrive in their mission to tackle global health challenges, meet the demands of our healthcare system and address some of the world’s most pressing unmet medical needs. Furthermore, we are preparing the next generation of pharmacists and pharmaceutical scientists to do the same.”
The Faculty is world-renowned for its high profile research through the Monash Institute of Pharmaceutical Sciences (MIPS), led by Professor Chris Porter.
In 2023 MIPS continued to advance Australia’s biomedical research capabilities with the establishment of several new ventures, including the launch of MedChem Australia, a collaboration between Monash, the Walter and Eliza Hall Institute, and The University of Sydney, to accelerate early-stage drug discovery projects towards clinical trials and, ultimately, create new medicines for a broad range of diseases.
Twenty twenty-three also saw the launch of the Monash-Moderna Quantitative Pharmacology Accelerator, a five-year partnership with Moderna that aims to drive advancements in mRNA medicines, along with the launch of the Monash Quality of Medicines Initiative to bring world class pharmaceutical science expertise to address issues of medicines quality in resource-constrained settings.
“As the world collectively faces the rise of a number of health challenges, our pharmacists and pharmaceutical scientists have remained at the forefront of research that drives the discovery and development of new and improved drugs, and enhances the safe and effective use of medicines,” said Professor Porter.
Professor Christopoulos says that the Faculty is known as much for the quality of its education as for the quality of its research.
“Our Pharmacy degree has long been considered the leading program of its kind in Australia and, together with the extraordinary growth in our more recent Pharmaceutical Science offerings, it highlights and addresses the unprecedented demand for healthcare workforce development opportunities nationally and internationally. Both programs have a very strong emphasis on communication, problem solving and highly engaging content that focus on ‘learning by doing’.”
Overall, Monash University has strengthened its reputation as a global top-50 university with an increase in the number of subjects ranking in the top 50. A total of 21 Monash subjects placed in the top 50 globally, including one subject – Marketing – entering the top 50 with its first-ever ranking in the 2024 list.
The QS World University Rankings by Subject assess the performance of more than 1500 universities worldwide. The rankings are compiled from an analysis of more than 16.4 million unique papers, 117.8 million citations and global surveys by employers and academics.
Ends
Contact details:
Kate Carthew
